Document:

<PAGE>

                                           ***Text Omitted and Filed Separately
                                           Confidential Treatment Requested
                                           Under 17 C.F.R. Sections 200.80(b)(4)
                                           And 240.24b-2

                                                                   Exhibit 10.67

                                LICENSE AGREEMENT

This license agreement (the "Agreement"), effective as of December 31, 2004 (the
"Effective Date") is by and between Gen-Probe Incorporated ("Gen-Probe"), a
Delaware corporation having an address at 10210 Genetic Center Drive, San Diego,
CA 92121 and Corixa Corporation ("Corixa"), a Delaware corporation, having an
address at 11900 9th Avenue, Suite 1100, Seattle, WA 98101, (collectively the
"parties" and each a "party").

1.   BACKGROUND

     1.1. Corixa controls certain intellectual property rights related to
          nucleic acids, antigens and antibodies that may be useful components
          in cancer diagnostic products.

     1.2. Gen-Probe desires to obtain a license under Corixa's rights to such
          intellectual property in order to make, use and sell certain
          diagnostic products that incorporate such components.

2.   DEFINITIONS

     2.1. "AFFILIATE" shall mean, with respect to either party hereto, any
          corporation, partnership, or organization which such party directly or
          indirectly controls, is controlled by or is under common control with.
          For the purposes of this definition "control" shall mean holding of
          fifty percent (50%) or more of the voting stock or other ownership
          interest of the corporation or business entity involved, or if it
          possesses the power to directly or indirectly control the management
          and policies of the other corporation or business entity.

     2.2. "ANALYTE SPECIFIC REAGENT" OR "ASR" shall mean diagnostic reagents
          used or sold for use by Third Parties with General Purpose Reagents
          (GPR) under applicable regulations of the U.S. Food and Drug
          Administration, where the ASR's and GPR's are not considered to
          comprise a diagnostic test kit.

     2.3. "CONFIDENTIAL INFORMATION" shall mean, subject to the terms of Article
          9 of this Agreement, all information and materials received by either
          party from the other party pursuant to this Agreement that is marked
          as "confidential", "restricted", "proprietary" or the like, or which
          is stated to be such within sixty (60) days after its disclosure if
          transmitted orally, or which by its nature is information normally
          intended to be held in confidence, whether in the form of tangible
          media, oral disclosures or otherwise. The nature and terms of this
          Agreement shall be deemed to be Confidential Information.

     2.4. "CONTROL" OR "CONTROLLED" means with respect to any Know-How, Licensed
          Patents or other intellectual property rights, the possession by a
          party of the right, power and authority (whether by ownership, license
          or otherwise) to grant a license or sublicense to such Know-How,
          Licensed Patents or other

                                      -1-

<PAGE>

          intellectual property without violating the terms of any agreement or
          other arrangement with any Third Party.

   2.5.   "DIAGNOSTIC RESULT" shall mean one or more of the following
          determinations as they pertain to a discrete disease or condition: the
          presence or absence of the disease or condition, predisposition to or
          likelihood of contracting the disease or condition, monitoring the
          progress or decline of the disease or condition, predicting and/or
          monitoring the response to treatment of the disease or condition,
          prognosis relating to the disease or condition, and, identification of
          the origin of the tissue.

   2.6.   "END USER" shall mean those persons or entities who are not in the
          business of reselling products, and whose use of a product normally
          results in the product's consumption, destruction or loss of activity.

   2.7.   "FDA" shall mean the Food and Drug Administration of the United States
          or its foreign equivalent or counterpart, as applicable.

   2.8.   "FIELD" shall mean the field of [...***...] and [...***...].

   2.9.   "FIRST COMMERCIAL SALE" shall mean the first sale on a commercial
          basis after receiving Marketing Approval of any Licensed Product by
          Gen-Probe or its sub-licensees to a Third Party (excluding any
          Affiliate or sublicensee of Gen-Probe, unless such Affiliate or
          sublicensee is an End User), in any country, on a country-by-country
          basis.

   2.10.  "KNOW-HOW" means all trade secret or other information that is not
          generally known or biological materials, including, without
          limitation, cells, cell lines, genes, gene fragments, gene sequences,
          probes, DNA, RNA, cDNA libraries, proteins, peptides, polypeptides,
          plasmids, vectors, expression systems, organisms, biological
          substances, and any constituents, progeny or replications thereof or
          therefrom, reagents, chemical compounds, inventions, improvements,
          practices, formula, trade secrets, techniques, methods, procedures,
          knowledge, know-how, skill, experience, results, test data (including,
          without limitation, pharmacological, toxicological, animal model and
          clinical test data), analytical and quality control data and any
          marketing, pricing, distribution, cost, sales, manufacturing, patent
          or data descriptions, whether or not patentable, that are owned or
          Controlled by Corixa and that are related to the Licensed Products and
          the monoclonal antibody-producing hybridoma cell line clones
          identified in Exhibit B.

   2.11.  "LICENSED PATENTS" shall mean the U.S. and foreign patents (including
          without limitation any reissues, reexaminations, extensions,
          divisions, renewals, substitutions, confirmations, registrations,
          revalidations, revisions and additions of or to any of the foregoing)
          and patent applications (including without limitation any renewal,
          division, continuation, continued prosecution application or
          continuation-in-part of any of such applications) set forth in Exhibit
          A.

   2.12.  "LICENSED PRODUCT" shall mean any product in the Field that
          incorporates Know-How or at least one (1) Marker, the manufacture,
          use, sale, or import of which by Gen-Probe or a Gen-Probe sublicensee,
          would, but for the license granted herein, infringe one (1) or more of
          the Valid Claims of one (1) or more

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -2-

<PAGE>

          Licensed Patents or, in the case of Know-How, was utilized in the
          development, manufacturing, use or sale of a product.

   2.13.  "MARKER" shall mean a specific nucleic acid composition (or
          derivative thereof), protein composition (or derivative thereof), or
          antibody directed to the specific protein composition and methods
          employing or assaying for the presence of such compositions for
          providing a Diagnostic Result. Such nucleic acid composition may be a
          polynucleotide or fragment of a polynucleotide and such protein
          composition may be a polypeptide or fragment of a polypeptide.

   2.14.  "MARKETING APPROVAL" shall mean, with respect to a particular Licensed
          Product in a particular country, the date upon which the last of all
          governmental or regulatory approvals required for the sale of such
          Licensed Product in that country has been granted.

   2.15.  "NET SALES" shall mean the gross amount invoiced to non-affiliated
          Third Parties by Gen-Probe, its Affiliates, or its sublicensees in
          arms length transactions, less the following reasonable and customary
          accrual-basis deductions to the extent applicable to such invoiced
          amounts (to the extent each is actually incurred and included in the
          invoiced gross sales price) in accordance with generally accepted
          accounting practices ("US GAAP"), as consistently applied by Gen-Probe
          for financial reporting purposes: (i) [...***...], [...***...] and
          [...***...], [...***...], or [...***...] (including, without
          limitation, [...***...]); (ii) [...***...] for [...***...],
          [...***...] or [...***...] or [...***...]; [...***...]; [...***...];
          or [...***...]; (iii) [...***...], [...***...] and [...***...],
          [...***...], [...***...], [...***...] and other [...***...] (including
          [...***...], but excluding what is commonly known as [...***...]); and
          (iv) [...***...] or [...***...] given or made for [...***...],
          [...***...] and [...***...]. The specific deductions taken under, and
          the general provision of, (i) through (iv) above shall be adjusted
          periodically as necessary to reflect amounts actually incurred. For
          the avoidance of doubt, a Licensed Product sale shall be deemed to
          occur when shipment of such Licensed Product is recognized by
          Gen-Probe, its Affiliates, or its sublicensees as revenue under US
          GAAP, consistently applied.. A "sale" shall also include a transfer or
          other disposition for consideration other than cash, in which case
          such consideration shall be valued at the fair market value thereof.
          Transfers or dispositions for charitable or promotional purposes or
          for pre-clinical, clinical, regulatory or governmental purposes prior
          to receiving Marketing Approval are not considered a "sale."

          2.15.1. In the event that a Licensed Product is sold pursuant to a
               "reagent/rental" program or comparable sale or lease program,
               that portion of the invoiced price of such Licensed Product
               reasonably allocable to recovery of the cost of the
               instrumentation shall also be deducted in determining the Net
               Sales of such Licensed Product; provided that Gen-Probe shall not
               market Licensed Products and instrumentation in such a manner as
               to distort the relative profitability of the Licensed Products
               when considered in light of Gen-Probe's standard accounting
               practices and standard marketing practices within the clinical
               diagnostic industry.

   2.16.  "ROYALTY TERM" means

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -3-

<PAGE>

          2.16.1. With respect to each Licensed Product in each country of the
               Territory, considered on a country-by-country basis, the period
               beginning upon the Effective Date and extending for so long as a
               Valid Claim remains in effect and would be infringed by such
               Licensed Product but for the license granted by this Agreement;

          2.16.2. Notwithstanding the above, in the event that termination of
               the Royalty Term as computed Section 2.16.1 is less than
               [...***...] years from the First Commercial Sale of such Licensed
               Product anywhere in the Territory, then the Royalty Term in each
               country shall extend until the [...***...] anniversary of the
               date computed in Section 2.16.1.

   2.17.   "TERRITORY" means the entire world.

   2.18.   "THIRD PARTY" shall mean any person or entity other than Gen-Probe,
          Corixa or their respective Affiliates.

   2.19.   "THERAPEUTIC DRUG MONITORING" OR "TDM" shall mean the use of a
          Marker(s) solely for the purpose of pre-screening human patients to
          determine eligibility for therapeutic treatment with an Active
          Response Product (as defined below) that incorporates such Marker(s)
          and/or a Passive Response Product (as defined below) that incorporates
          such Marker(s), or for [...***...] receiving such an Active Response
          Product and/or Passive Response Product, as applicable, either during
          the clinical phase of development of such Active Response Product
          and/or Passive Response Product, as applicable, or following
          commercialization thereof. For further clarification, use of a product
          is outside the Field if such product is associated commercially with
          Active Response Product and/or Passive Response Product administration
          and cannot be sold purely as a diagnostic product used for
          [...***...], [...***...] or [...***...] or for monitoring patient
          response to non-Active Response Product(s) or non-Passive Response
          Product(s). For purposes of this Agreement, "Active Response Product"
          shall mean a [...***...] containing [...***...], [...***...] presented
          in a [...***...] or as a [...***...]. For purposes of this Agreement,
          "Passive Response Product" shall mean an [...***...]a [...***...], or
          [...***...] to a [...***...] administered to patients [...***...] a
          [...***...].

   2.20.   "VALID CLAIMS" shall mean with respect to each country in the
          Territory, a claim of an issued, unexpired patent or any pending
          patent applications included in the Licensed Patents, which patent has
          not been (a) held invalid or unenforceable by a final decision of a
          court or governmental agency of competent jurisdiction, which decision
          is unappealable or was not appealed within the time allowed therefore,
          or (b) admitted in writing to be invalid or unenforceable by the
          holder(s), whether by means of reissue, disclaimer or otherwise.

3.   GRANTS

     3.1. LICENSE AND RESTRICTIONS. (a) Corixa hereby grants to Gen-Probe a
          royalty-bearing, exclusive right and license, with the right to
          sublicense as provided in

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -4-

<PAGE>

          Section 3.2, under the Licensed Patents and Know-How, to conduct
          research and to develop, make and have made, sell, offer to sell and
          have sold, import and have imported Licensed Products in the Field in
          the Territory; provided, however, that such license grant is subject
          to the restrictions set forth in Section 3.1(b) below.

               (b) The license granted by Corixa to Gen-Probe in Section 3.1(a)
          above is subject to the following restrictions:

                  (i)    it is a [...***...] right as it applies to Licensed
                         Products in the field of [...***...],

                  (ii)   all rights to the [...***...], [...***...] and
                         [...***...] conducted for the purpose of diagnosing a
                         condition or disease in humans and for sale as a
                         research diagnostic for the [...***...] and [...***...]
                         are excluded from such license grant,

                  (iii)  it is a [...***...] right as it applies to (a)
                         [...***...], [...***...] and [...***...] conducted for
                         the purpose of [...***...]or [...***...] in [...***...]
                         for the [...***...] and (b) [...***...] for the
                         [...***...] and

                  (iv)   it does not include any rights related to (a) the
                         [...***...] or (b) the [...***...] or (c) the
                         development of diagnostics for the detection of
                         [...***...] the [...***...] listed on Exhibit C that
                         Corixa has already licensed to a Third Party.

          As used in this Section 3.1(b), the term "co-exclusive" shall mean
          that at no time during the term of such license or right shall Corixa
          grant a right or license in a given country or territory to more than
          one entity in addition to the rights and licenses granted under this
          Agreement to Gen-Probe, its Affiliates and sublicensees.

     3.2.    SUBLICENSES. The grant under Section 3.1 above hereby includes the
          right of Gen-Probe to grant sublicenses to its Affiliates and to Third
          Parties within the scope of the license and rights granted to
          Gen-Probe in Section 3.1. Any sublicense agreement by Gen-Probe to an
          Affiliate or a Third Party hereunder shall include provisions
          concerning intellectual property and confidentiality at least as
          protective of Corixa as those set for herein and such agreement shall
          consistent with all terms and conditions of this Agreement. Within
          thirty (30) days following execution of any sublicense of any rights
          hereunder, Gen-Probe shall provide to Corixa a copy of such sublicense
          agreement.

4.   TECHNOLOGY TRANSFER

     4.1.    TECHNOLOGY TRANSFER. Within thirty (30) days of GenProbe's payment
          to Corixa of the license fee set forth in Section 5.1(a) and a written
          request from Gen-Probe, Corixa shall transfer to Gen-Probe, at
          Gen-Probe's expense and in

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -5-

<PAGE>

          a format reasonably acceptable to Gen-Probe, a selection of materials,
          information, data and procedures that currently exist and that are in
          Corixa's possession and that, in each case, comprise the "best
          practices" Know-How as of such date and any other Know-How that is
          necessary or reasonably useful for Gen-Probe and that is in Corixa's
          possession. Following such initial transfer, to the extent the parties
          identify any additional materials and/or information that is in
          Corixa's possession (including without limitation, any materials,
          protocols, reagents, compounds, biological materials, assays, data,
          reports, analyses and other information) relating to the rights
          granted under this Agreement that would be necessary or reasonably
          useful for Gen-Probe, and not already disclosed to Gen-Probe by Corixa
          hereunder, Gen-Probe may request that Corixa provide, and Corixa shall
          provide, at Gen-Probe's expense, a further reasonable number of such
          materials or information within thirty (30) days from such request.

5.   PAYMENTS

     5.1.    MILESTONE PAYMENTS. Gen-Probe shall pay to Corixa the following
          non-refundable, non-creditable fees to the extent they become due
          during any Royalty Period in the United States computed under Section
          2.16.1:

          (a)  One Million Six Hundred Thousand Dollars ($1,600,000) within
               thirty (30) days of the Effective Date.

          (b)  One Million Six Hundred Thousand Dollars ($1,600,000) by January
               31st, 2006.

          (c)  One Million Six Hundred Thousand Dollars ($1,600,000) by January
               31st, 2007.

          (d)  [...***...] upon the [...***...] submission of an application to
               the FDA for approval to market a Licensed Product.

          (e)  [...***...] upon the [...***...] of the first [...***...].

          (f)  [...***...] upon the [...***...] Marketing Approval of a Licensed
               Product.

          (g)  [...***...] upon each submission of an application to the FDA for
               approval to market a Licensed Product that includes any Marker
               for which such fee has not already been paid.

          (h)  [...***...] upon Marketing Approval of each Licensed Product
               incorporating one or more Markers for which such fee has not
               already been paid.

          (i)  [...***...] upon reaching Net Sales [...***...] in a calendar
               year for each Licensed Product for which such fee has not already
               been paid.

          (j)  [...***...] upon reaching Net Sales of [...***...] in a calendar
               year for each Licensed Product incorporating one or more Markers
               for which such fee has not already been paid.

          (k)  In the event that a Licensed Product is directed at [...***...]
               or more different Markers and one of the Markers was used in a
               Licensed Product

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -6-

<PAGE>

               incorporating [...***...] or [...***...]Markers for which
               Gen-Probe had reached Net Sales of [...***...] in a calendar
               year, then the milestone payments set forth in Sections 5.1(g),
               5.1(h), 5.1(i) and 5.1(j) shall be [...***...] for such Licensed
               Product of the type that is described in this Section 5.1(k).

     5.2. ROYALTY PAYMENTS. In addition to the amounts payable pursuant to
          Section 5.1 above and subject to Section 6.1, below, Gen-Probe shall,
          until the end of the applicable Royalty Term, pay Corixa a royalty on
          Net Sales of all Licensed Products as follows:

          (a)  With respect to Net Sales of Licensed Products that are
          [...***...] for which Marketing Approval has not been obtained a
          royalty of [...***...] shall apply.

          (b)  With respect to Net Sales of Licensed Products for which
          Marketing Approval has been obtained a royalty of [...***...]
          shall apply.

     5.3. SUBLICENSING REVENUE. In addition to the foregoing, Gen-Probe shall
          pay to Corixa a sum equal to [...***...] of all amounts received by
          Gen-Probe in consideration of Gen-Probe sublicensing of any of its
          rights to the Licensed Patents and/or Know-How granted hereunder to
          Third Parties, such amounts to include, without limitation,
          [...***...], [...***...], [...***...], [...***...] and [...***...]. In
          addition, Gen-Probe shall, until the end of the applicable Royalty
          Term, pay Corixa a royalty on Net Sales of all Licensed Products by
          its sublicensees equal to the lesser of (i) [...***...] of the royalty
          paid by Gen-Probe's sublicensee to Gen-Probe or (ii) the royalty that
          would otherwise be paid by Gen-Probe to Corixa pursuant to Section 5.2
          above as if it were Gen-Probe's Net Sales; provided, however, that in
          no event shall the royalties payable to Corixa ever be less that
          [...***...] of the Net Sales of Licensed Products, unless the
          circumstances described in Section 6.1(b) below exist, in which case,
          the royalty payable to Corixa shall never be less than [...***...] of
          Net Sales of such Licensed Product.

6.   ADJUSTMENTS TO ROYALTY PAYMENTS

     6.1. ADJUSTMENTS. The royalty rates payable pursuant to Section 5.2 above
          may be reduced as follows:

          (a)  If a Licensed Product sold in a particular country or territory
               is at the time of sale not covered by a Valid Claim of at least
               one Licensed Patent in such country, for example, due to Corixa's
               failure to apply for patents, or the expiration or invalidation
               of all relevant Licensed Patents in such country by final
               judicial or patent office action without possibility of appeal or
               reinstatement, then the applicable royalty rate stated in Section
               5.2 with respect to Net Sales of such Licensed Product sold in
               that country under those conditions shall be reduced by
               [...***...]. However, if such Licensed Product is later covered
               by a Valid Claim of at least one Licensed Patent in such country
               or territory, the full royalty provided for in

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -7-

<PAGE>

               Section 5.2 shall be due as provided therein for the period that
               such patent is a Licensed Patent covering such country.

          (b)  Where the manufacture, sale, offer for sale, use or importation
               of a Licensed Product infringes the proprietary rights of a Third
               Party due to the incorporation of a Corixa-owned or Controlled
               Marker into the Licensed Product, and Gen-Probe or any of its
               sublicensees is required to pay any royalties or other amounts as
               a result of such infringement (the "Third Party Amounts"), the
               royalties payable under Section 5.2 shall be reduced by
               [...***...] of the amount of the Third Party Amounts, provided,
               however, that the royalties payable by Gen-Probe to Corixa under
               Section 5.2 above shall in no event be reduced to less than
               [...***...] as a result of this Section 6.1(b).

          (c)  In the event that the Licensed Product is a diagnostic assay that
               includes one or more Corixa-owned or Controlled Markers and other
               Markers in-licensed by Gen-Probe from a Third Party, then the
               royalties payable under Section 5.2 shall be reduced by
               [...***...] of the amount of royalties payable by Gen-Probe to
               such Third Party for such in-license, provided, however, that the
               royalties payable by Gen-Probe to Corixa under Section 5.2 above
               shall in no event be reduced to less than [...***...] as a result
               of this Section 6.1(c).

7.   REPORTS AND PAYMENT TERMS

     7.1. REPORTS. Within sixty (60) days following the close of each calendar
          quarter, Gen-Probe will submit to Corixa a report of Gen-Probe's and
          its sublicensee(s)' Net Sales and any payments due based on such Net
          Sales under the terms of this Agreement for such period.

     7.2. TIMING OF PAYMENTS. Payments due as set forth in statements pursuant
          to Section 7.1 will be paid with the submission of such reports to
          Corixa. Except as otherwise set forth in Section 5.1(a), all other
          payments due under the terms of this Agreement shall be paid within
          [...***...] days of the relevant event on which such payment is based.

     7.3. LATE PAYMENTS. All amounts past due shall bear interest from the date
          they are due until the date they are paid the rate of [...***...] per
          annum.

     7.4. CURRENCY EXCHANGE. The remittance of all amounts payable to Corixa
          under this Agreement (including royalties for Net Sales of Licensed
          Products outside the United States) will be made by Gen-Probe,
          notwithstanding currency restrictions or regulations in any country
          where the Licensed Products are sold, in United States dollars at the
          official rate of exchange (as quoted by Citibank NA and calculated as
          the average of the exchange rates at noon Pacific Time on the last
          business day of the second and third months of the applicable calendar
          quarter) of the currency of the country from which the royalties are
          payable.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -8-

<PAGE>

     7.5.  AUDITS.

          (a) Upon the written request of Corixa and not more than [...***...]
          in each calendar year, Gen-Probe and its Affiliates shall permit an
          independent certified public accounting firm of nationally recognized
          standing, selected by Corixa and reasonably acceptable to Gen-Probe,
          at Corixa's expense, to have access during normal business hours to
          such of the records of Gen-Probe and its Affiliates as may be
          reasonably necessary to verify the accuracy of the royalty reports
          hereunder for any year ending not more than [...***...] months prior
          to the date of such request. The accounting firm shall disclose to
          Corixa only whether the reports are correct or not and the specific
          details concerning any discrepancies.

          (b) If such accounting firm concludes that additional royalties were
          owed during the audited period, Gen-Probe shall pay such additional
          royalties within thirty (30) days of the date Corixa delivers to
          Gen-Probe such accounting firm's written report so concluding. The
          fees charged by such accounting firm shall be paid by Corixa;
          provided, however, that if the audit discloses that the royalties
          payable by Gen-Probe for such period are more than [...***...] of the
          royalties actually paid for such period, then Gen-Probe shall pay the
          reasonable fees and expenses charged by such accounting firm.

          (c) Corixa shall treat all financial information subject to review
          under this Section 7.5 as Confidential Information, and shall cause
          its accounting firm to retain all such financial information in
          confidence. Corixa shall cause a copy of any reports provided by such
          accounting firm to Corixa hereunder also to be provided to Gen-Probe.

     7.6. PAYMENT METHOD. All payments hereunder shall be in U.S. Dollars by
          bank wire transfer in immediately available funds from a United States
          bank located in the United States to the following Corixa account (or
          such other bank account as designated by Corixa from time to time):

                                        Name: [...***...]
                                        Address:  [...***...]
                                                  [...***...]
                                        Account: [...***...]
                                        Account #:[...***...]

          If Gen-Probe is required to withhold and remit any tax to the tax
          authorities in any regard to any amount payable to the Corixa, such
          amount shall be withheld and paid to the such tax authority. In such
          event, Gen-Probe shall notify Corixa and promptly furnish with copies
          of any documentation evidencing such withholding.

8.   PATENT PROSECUTION AND LITIGATION

     8.1. As between the parties, Corixa shall have [...***...] and [...***...]
          regarding any prosecution or maintenance of the Licensed Patents;
          provided, however, that Corixa may not file any Licensed Patents that
          claim [...***...], and/or [...***...] unless requested to do so in
          advance by Gen-Probe. Any such filing or

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -9-

<PAGE>

          prosecution shall be performed by legal counsel selected by Gen-Probe
          and approved by Corixa, which consent shall not be unreasonably
          withheld. Corixa shall keep Gen-Probe reasonably informed of the
          course of patent prosecution or other proceedings relating to the
          Licensed Patents. Gen-Probe shall hold all information disclosed to it
          under this Section 8.1 as Confidential Information.

             (i)    Gen-Probe shall reimburse Corixa [...***...] incurred after
                    the Effective Date in connection with the filing,
                    prosecuting and maintenance of the Licensed Patents that
                    claim [...***...], and/or [...***...] whether or not Corixa
                    has a [...***...] development program, and for all Licensed
                    Patents for programs in which Corixa does not have a
                    [...***...] development program ongoing.

             (ii)   Gen-Probe shall have the right to terminate, on thirty days
                    written notice to Corixa and on a country-by-country basis,
                    its obligation to reimburse Corixa for the costs of
                    prosecuting and maintaining any or all claims in any
                    Licensed Patents that claim [...***...], and/or [...***...].
                    In the event that Gen-Probe elects not to fund the
                    prosecution or maintenance of any such claim of any Licensed
                    Patents in a country, Gen-Probe shall relinquish all rights
                    under this Agreement with respect to such claim(s) and the
                    license granted hereunder shall terminate as to such
                    claim(s) in such country.

             (iii)   In connection with the filing, prosecuting and maintenance
                    of the Licensed Patents that do not claim [...***...] and
                    for which Corixa has a [...***...] development program
                    ongoing and where the making, using, selling, and/or
                    importing of Licensed Product would infringe a Valid Claim
                    but for the license granted by Corixa hereunder, Corixa
                    shall first give Gen-Probe the opportunity to consider if it
                    has any interest in pursuing such claims. Gen-Probe shall
                    inform Corixa in writing regarding its decision to pursue
                    such claims within thirty (30) days of receiving a written
                    description of the proposed claims from Corixa. In the event
                    that Gen-Probe elects not to pursue such claims, Gen-Probe
                    shall have no obligation to reimburse Corixa for any costs
                    that may be incurred for the filing, prosecution or
                    maintenance of such claims and Gen-Probe shall relinquish
                    all future rights under the Agreement to such claims. In the
                    event Gen-Probe elects to pursue such claims, Gen-Probe
                    shall reimburse Corixa for [...***...] of the costs incurred
                    after the Effective Date in connection with the filing,
                    prosecuting and maintenance of the Licensed Patents that do
                    not claim [...***...], and/or [...***...] and for which
                    Corixa has a [...***...] development program ongoing and
                    where the making, using, selling, and/or importing of
                    Licensed Product would infringe a Valid Claim but for the
                    license granted by Corixa. Notwithstanding the foregoing,
                    such costs shall not in any event exceed $[...***...] per
                    year.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -10-

<PAGE>

     8.2. ENFORCEMENT. A party will notify the other party if it becomes aware
          of the activities of any Third Party which are believed to infringe
          any of the Licensed Patents. Subject to the parties entering into a
          mutually acceptable joint defense agreement or both parties agreeing
          that a joint defense agreement is not necessary, the parties shall
          consult as to potential strategy or strategies to terminate such
          alleged infringement without litigation. Gen-Probe and/or its
          sublicensee(s), at its/their sole discretion, may take reasonable
          actions to terminate such alleged infringement without litigation.
          Gen-Probe and/or its sublicensee(s) shall promptly notify Corixa in
          writing of its/their intention with regard to any such infringement.
          If the efforts of Gen-Probe and/or its sublicensee(s) are not
          successful in terminating the alleged infringement, Gen-Probe and/or
          its sublicensee(s) shall have the right, but not the obligation, to
          commence any action or proceeding against such infringement, at
          its/their own cost. To the extent Gen-Probe and/or its sublicensee(s)
          takes such action, Gen-Probe and/or its sublicensees shall control any
          such action undertaken by Gen-Probe and/or its sublicensee(s) against
          such an infringer, and Gen-Probe and/or its sublicensee(s) may enter
          into settlements, stipulated judgments or other arrangements
          respecting such infringement, at its/their own expense; provided
          however, that if such proposed settlements, judgments or arrangements
          would result in reduction or elimination of payments to Corixa under
          this agreement, they shall be subject to Corixa's consent, not to be
          unreasonably withheld. If Gen-Probe and/or its sublicensee(s)
          commences such infringement action, Corixa agrees to execute all
          papers and to perform such other acts as may be reasonably required
          (including consent to be joined as nominal party plaintiffs in such
          action). Gen-Probe and/or its sublicensee(s) shall reimburse Corixa
          for its out-of-pocket expenses relating to such infringement action,
          and Corixa may, at its option and expense, be represented by counsel
          of its choice. Any damages or other recovery from an infringement
          action undertaken by Gen-Probe and/or its sublicensee(s) pursuant to
          this section, after reimbursement of any reasonable litigation
          expenses of the Parties and/or their sublicensee(s), shall be divided
          equally between Gen-Probe and/or its sublicense(s) on the one hand and
          Corixa on the other. If Gen-Probe and/or its sublicensee(s) fail to
          bring such infringement action within (i) 60 days following notice of
          alleged infringement or (ii) 30 days before the time limit, if any,
          set forth in the appropriate laws and regulations for the filing of
          such actions, whichever comes first, Corixa shall have the right to
          bring and control any such action at its own expense and by counsel of
          its own choice, and Gen-Probe shall have the right, at its own
          expense, to be represented in any such action by counsel of its own
          choice. Corixa shall retain any damages or other recovery from an
          infringement action undertaken by Corixa.

9.   CONFIDENTIALITY AND PUBLICITY

     9.1. CONFIDENTIALITY. During the term of this Agreement and for [...***...]
          thereafter, all Confidential Information disclosed by one party to the
          other shall not be used by the receiving party except in connection
          with the activities contemplated by this Agreement, shall be disclosed
          to and used by only such personnel of the receiving party that shall
          have a need to know such information, shall be maintained in
          confidence by the receiving party, and shall not be disclosed by the
          receiving party to any other person, firm or agency,

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -11-

<PAGE>

          governmental or private, without the prior written consent of the
          disclosing party, except to the extent Confidential Information is:

          (a) known by or in possession of the receiving party at the time of
          its receipt as documented in written records;

          (b) independently developed outside the scope of this Agreement by
          employees of the receiving party having no access to or knowledge of
          the Confidential Information disclosed hereunder as documented in
          written records;

          (c) in the public domain at the time of its receipt or thereafter
          becomes part of the public domain through no fault of the receiving
          party;

          (d) received without an obligation of confidentiality from a Third
          Party having the right to disclose such information;

          (e) required to be disclosed to governmental agencies in order to gain
          approval to sell Licensed Products, or disclosure is otherwise
          required by law, regulation or governmental or court order (so long as
          the receiving party provides notice of such disclosure, seeks to
          obtain protective orders or other available confidentiality treatment
          and, in the case of disclosures to the U.S. Securities and Exchange
          Commission provides an opportunity to review the disclosure prior to
          making such disclosure);

          (f) released from the restrictions of this Sections 9.1 by the express
          written consent of the disclosing party; or

          (g) disclosed to agents, consultants, assignees, sublicensees or
          subcontractors of Gen-Probe or Corixa or their Affiliates which have a
          need to know such information in connection with the performance of
          this Agreement, provided that such persons are or agree to be subject
          to the provisions of this Section 9.1 or substantially similar
          provisions.

     9.2. PUBLICITY. Neither party will make, issue or release any public
          announcement, press release, statement or acknowledgement of the
          existence of, or reveal publicly the terms, conditions and status of,
          the transactions contemplated herein, without the prior written
          consent of the other party as to the content and time of release of
          and the media in which such statement or announcement is to be made;
          provided, however, that in the case of announcements, statements,
          acknowledgments or revelations which either party is required by law
          to make, issue or release, the making issuing or releasing of any such
          announcement, statement, acknowledgement or revelation by the party so
          required to do so by law shall not constitute a breach of this
          Agreement if such party shall have given, to the extent reasonably
          possible, not less than two (2) calendar days prior notice to the
          other party, and shall have attempted, to the extent reasonably
          possible, to clear such announcement, statement acknowledgement or
          revelation with the other party. No other party shall use the name of
          the other party or any of its Affiliates for advertising or
          promotional purposes without the prior written consent of such other
          party. The parties acknowledge that Corixa will issue a press release
          shortly after the execution of this Agreement, the content of which
          shall be agreed to by the parties in advance of the issuance of the
          release.

                                      -12-

<PAGE>

10.  TERM, TERMINATION, AND SURVIVAL

     10.1. TERM. This Agreement shall commence on the Effective Date and, unless
          sooner terminated pursuant to Sections 10.2, 10.3 or 10.4, shall
          terminate upon the expiration of Gen-Probe's obligation to pay
          royalties under Section 5.2, above.

     10.2. TERMINATION BY GEN-PROBE. Gen-Probe may terminate this Agreement, in
          its sole discretion, upon [...***...] days prior written notice to
          Corixa, provided Gen-Probe pays Corixa all monies owed Corixa as of
          the effective date of such termination and without prejudice to
          Corixa's rights under this Agreement that accrued prior to such
          termination.

     10.3. TERMINATION FOR CAUSE. In the event of a material breach by either
          party, the other party may terminate this Agreement by giving the
          breaching party notice of such material breach. The party receiving
          such notice shall have [...***...] days from the date of receipt
          thereof to cure such material breach. If such material breach is not
          cured within such [...***...] day period, then the non-breaching party
          shall have the right to terminate this Agreement effective as of the
          end of such period. In the event such material breach is cured during
          such period, such notice shall be of no force or effect and this
          Agreement shall not be terminated.

     10.4. INSOLVENCY OR BANKRUPTCY. This Agreement may be terminated by a Party
          upon written notice to the other Party in the event the other party
          becomes insolvent or a petition in bankruptcy or for corporate
          reorganization or for any similar relief is filed by or against the
          other Party, or a receiver is appointed with respect to any of assets
          of the other Party, or a liquidation proceeding is commenced by or
          against the other Party.

     10.5. EFFECT OF TERMINATION.

          (a)  Upon expiration of this Agreement under Section 10.1, Gen-Probe
               shall have a paid-up, non-exclusive license under the Corixa
               Know-How in the Territory in respect of Licensed Products.

          (b)  Termination of this Agreement for any reason shall not release
               either Party hereto from any liability which, at the time of such
               termination, has already accrued to the other Party or which is
               attributable to a period prior to such termination, nor preclude
               either Party from pursuing any rights and remedies it may have
               hereunder or at law or in equity which accrued or are based upon
               any event occurring prior to such termination.

          (c)  In the event of termination of this Agreement by Gen-Probe
               pursuant to Sections 10.3 or 10.4, in addition to those
               provisions surviving under Section 10.6 the rights and licenses
               granted by Corixa to Gen-Probe under Article 3 shall survive for
               so long as Gen-Probe continues to make its payment obligations to
               Corixa as set forth in Article 5.

     10.6  SURVIVAL. Sections 10.5, 11.4, 11.5 11.6, this Section 10.6 and
          Articles 2, 9, 12 and 14of this Agreement shall survive expiration or
          termination of this Agreement for any reason.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -13-

<PAGE>

11.  WARRANTIES, REPRESENTATIONS, AND INDEMNIFICATIONS

     11.1. DISCLAIMER. OTHER THAN AS EXPRESSLY SET FORTH HEREIN, CORIXA MAKES NO
          REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE
          LICENSED PRODUCTS, KNOW-HOW, LICENSED PATENTS, INVENTIONS OR
          PROPRIETARY INFORMATION, INCLUDING WITHOUT LIMITATION, ANY WARRANTY OF
          NON-INFRINGEMENT, PATENTABILITY, MERCHANTABILITY OR FITNESS FOR A
          PARTICULAR PURPOSE.

     11.2. CORIXA REPRESENTATIONS AND WARRANTIES. Corixa represents and warrants
          that: (i) it is a corporation duly organized validly existing and in
          good standing under the laws of Delaware; (ii) all necessary consents,
          approvals and authorizations of all governmental authorities and other
          persons or entities required to be obtained by Corixa in connection
          with this Agreement have been obtained; (iii) the execution, delivery
          and performance of this Agreement have been duly authorized by all
          necessary corporate action on the part of Corixa; (iv) as of the
          Effective Date and to its knowledge, it is the sole and exclusive
          owner or exclusive licensee of all right, title and interest in the
          Licensed Patents; (v) as of the Effective Date and to its knowledge,
          it has the right to grant the rights, options and licenses granted
          herein, and the Licensed Patents are and will remain free and clear of
          any lien, encumbrance or security interest; (vi) subject to Section
          3.1(b) it has not previously granted, and will not grant during the
          term of this Agreement, any right, license or interest in or to the
          Licensed Patents, or any portion thereof, inconsistent with the
          rights, options and licenses granted to Gen-Probe herein; (viii) as of
          the Effective Date and to its knowledge, there are no threatened or
          pending actions, lawsuits, claims or arbitration proceedings in any
          way relating to the Licensed Patents; (ix) Corixa has included in the
          Licensed Patents all patent applications and patents owned or
          Controlled by Corixa that in Corixa's reasonable judgment are
          necessary for Gen-Probe to develop Licensed Products; (x) as of the
          Effective Date, Corixa has no actual knowledge of any Third Party
          patent, patent application or other intellectual property rights that
          would be infringed (i) by practicing any process or method or by
          making, using or selling any composition which is claimed or disclosed
          in the Licensed Patents or which constitutes Know-How, or (ii) by
          making, using or selling Licensed Products; and (xi) Corixa has no
          actual knowledge of any infringement or misappropriation by a Third
          Party of the Licensed Patents.

     11.3. GEN-PROBE REPRESENTATIONS AND WARRANTIES. Gen-Probe represents and
          warrants that: (i) it is a corporation duly organized validly existing
          and in good standing under the laws of the State of Delaware; (ii) all
          necessary consents, approvals and authorizations of all governmental
          authorities and other persons or entities required to be obtained by
          Gen-Probe in connection with this Agreement have been obtained; and
          (iii) the execution, delivery and performance of this Agreement have
          been duly authorized by all necessary corporate action on the part of
          Gen-Probe.

     11.4. INDEMNIFICATION BY GEN-PROBE. Subject to Section 11.6, Gen-Probe
          shall defend, indemnify and hold harmless each of Corixa and its
          directors, officers, and employees of Corixa and the successors and
          assigns of any of the foregoing (each a "Corixa Indemnitee") from and
          against any and all liabilities,

                                      -14-

<PAGE>

          damages, settlements, penalties, fines, costs or expenses (including,
          without limitation, reasonable attorneys' fees and other expenses of
          litigation) (collectively, "Liabilities") arising, directly or
          indirectly out of or in connection with Third Party claims, suits,
          actions, demands or judgments, to the extent they arise from: (i) the
          activities performed by or on behalf of Gen-Probe or its sublicensees
          hereunder in connection with the exercise of its licenses and rights
          hereunder or other usages of the Licensed Patents, or (ii) material
          breach by Gen-Probe of the representations and warranties under
          Section 11.3, except, in each case, to the extent caused by the gross
          negligence or willful misconduct of Corixa.

     11.5. INDEMNIFICATION BY CORIXA. Subject to Section 11.6, Corixa shall
          defend, indemnify and hold harmless each of Gen-Probe and its
          directors, officers, and employees of Gen-Probe and the successors and
          assigns of any of the foregoing (each a "Gen-Probe Indemnitee") from
          and against any and all Liabilities arising, directly or indirectly
          out of or in connection with Third Party claims, suits, actions,
          demands or judgments, relating to (i) the activities performed by or
          on behalf of Corixa or its sublicensees in connection with the
          exercise of its retained rights hereunder, or (ii) material breach of
          the representations and warranties under Section 11.2, except, in each
          case, to the extent caused by the gross negligence or willful
          misconduct of Gen-Probe.

     11.6. PROCEDURE. If a Corixa Indemnitee or Gen-Probe Indemnitee (the
          "Indemnitee") intends to claim indemnification under this Article 11,
          it shall promptly notify the other party (the "Indemnitor") in writing
          of such alleged Liability. The Indemnitor shall have the right to
          control the defense thereof with counsel of its choice as long as such
          counsel is reasonably acceptable to Indemnitee; provided, however,
          that any Indemnitee shall have the right to retain its own counsel at
          its own expense, for any reason, including if representation of any
          Indemnitee by the counsel retained by the Indemnitor would be
          inappropriate due to actual or potential differing interests between
          such Indemnitee and any other party reasonably represented by such
          counsel in such proceeding. The Indemnitee, its employees and agents,
          shall reasonably cooperate with the Indemnitor and its legal
          representatives in the investigation of any Liability covered by this
          Article 11. The obligations of this Article 11 shall not apply to
          amounts paid in settlement of any claim, demand, action or other
          proceeding if such settlement is effected without the consent of the
          Indemnitor, which consent shall not be withheld or delayed
          unreasonably. The failure to deliver written notice to the Indemnitor
          within a reasonable time after the commencement of any such action, if
          prejudicial to its ability to defend such action, shall relieve the
          Indemnitor of its obligations to the Indemnitee under this Article 11
          to the extent that such prejudice was caused by such delay. It is
          understood that only Corixa or Gen-Probe may claim indemnity under
          this Article 11 (on its own behalf or on behalf of its Indemnitees),
          and other Indemnitees may not directly claim indemnity hereunder.

12.  DISPUTE RESOLUTION

     12.1. Any controversy or claim arising out of or relating to this Agreement
          or the validity, inducement, or breach thereof (which shall not
          include issues regarding the validity or enforceability of patents),
          shall first be the subject of an

                                      -15-

<PAGE>

          attempted settlement by the parties' Chief Executive Officers or their
          designates. Such individuals shall make a good faith effort to reach
          an agreement settling the controversy or claim within 45 days of
          notification. The Parties agree that, except as otherwise set forth in
          Section 12.2 below, any dispute, controversy or claim arising out of
          or relating to this Agreement, or the breach, termination, or
          invalidity thereof, that is not resolved pursuant to the first
          sentence of this Section 12.1, shall be resolved through binding
          arbitration administered by the American Arbitration Association
          (unless otherwise agreed in writing by the parties) in accordance with
          its Commercial Arbitration Rules (unless otherwise agreed in writing
          by the parties), except as modified herein. Each party shall select
          one arbitrator and the two (2) arbitrators so selected shall choose a
          third arbitrator to resolve the dispute. A reasoned arbitration
          decision shall be rendered in writing within thirty (30) days of the
          conclusion of arbitration and shall be binding and not be appealable
          to any court in any jurisdiction. Such arbitration shall be concluded
          within six (6) months following the filing of the initial request for
          arbitration. The prevailing party may enter such decision in any court
          having competent jurisdiction. Unless otherwise mutually agreed upon
          by the parties, the arbitration proceedings shall be conducted at San
          Diego, California (if arbitration is requested by Corixa) or Seattle,
          Washington (if arbitration is requested by Gen-Probe), or such other
          location as may be agreed in writing by the parties. The parties agree
          that they shall share equally the cost of the arbitration filing and
          hearing fees, and the cost of the arbitrator. Each party must bear its
          own attorneys' fees and associated costs and expenses.

     12.2. DETERMINATION OF PATENTS AND OTHER INTELLECTUAL PROPERTY.
          Notwithstanding the foregoing, any dispute between the parties
          relating to the determination of validity of a party's patents or
          other issues relating to a party's intellectual property shall be
          submitted exclusively to the federal court located in San Diego,
          California (if such dispute is initiated by Corixa) or in Seattle
          Washington (if such dispute is initiated by Gen-Probe), or to a state
          court in such jurisdiction if the applicable rules of civil procedure
          preclude federal court jurisdiction, and the parties hereby consent to
          the jurisdiction and venue of such courts.

     12.3. NO CONSEQUENTIAL DAMAGES. NOTWITHSTANDING ANY OTHER PROVISION OF THIS
          AGREEMENT, EXCEPT WITH RESPECT TO ARTICLE 9 (CONFIDENTIALITY), IN NO
          EVENT SHALL A PARTY BE LIABLE FOR SPECIAL, INCIDENTAL OR CONSEQUENTIAL
          DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS
          HEREUNDER, INCLUDING WITHOUT LIMITATION, LOST PROFITS ARISING FROM OR
          RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF
          SUCH DAMAGES.

13.  DILIGENCE

     13.1. DILIGENCE. Gen-Probe agrees to use commercially reasonable efforts
          and diligence in conducting clinical studies, and to use commercially
          reasonable efforts and diligence to obtain the appropriate Marketing
          Approval for Licensed

                                      -16-

<PAGE>

          Products throughout the Territory. The foregoing diligence requirement
          is a material term of this Agreement. Notwithstanding any other
          provision of this Agreement, on or after the [...***...] of the
          Effective Date Corixa may partially terminate this Agreement, pursuant
          to Section 10.3 above, with respect to Gen-Probe's rights in any
          Corixa-owned or Controlled Marker licensed to Gen-Probe by Corixa
          under this Agreement unless Gen-Probe or a Gen-Probe sublicensee under
          this Agreement, has accomplished one of the following with respect to
          a Licensed Product that incorporates such Marker(s): (i) commenced
          sales of a Licensed Product in a lawful manner without the necessity
          of Marketing Approval, (ii) obtained Marketing Approval for a Licensed
          Product or (iii) initiated product development; provided, however,
          that Gen-Probe may extend the foregoing [...***...] by additional
          [...***...] by making an annual payment to Corixa beginning on the
          [...***...] of the Effective Date in the amount of [...***...]. During
          the Term, Gen-Probe agrees to provide Corixa with an annual
          development report within thirty (30) days after each fiscal year end
          which shall include product development timelines and anticipated
          milestones for Gen-Probe product development related to this
          Agreement. Such information shall be treated as "Confidential
          Information" for purposes of this Agreement.

14.  MISCELLANEOUS

     14.1. NOTICE. Any notice to be given hereunder by Gen-Probe to Corixa or by
          Corixa to Gen-Probe shall be in writing and delivered personally, sent
          by national overnight delivery service or postage prepaid registered
          or certified U.S. mail or transmitted by facsimile to the party to
          whom it is directed and shall be deemed given when delivered, if by
          personal delivery or overnight delivery service, or if sent by U.S.
          mail, three business days after deposit in the mail, or if sent by
          facsimile when received. Notice shall be sent to the addresses shown
          below or at such other address as such party shall have last given by
          notice to the other party.

         If to Corixa:              Corixa Corporation
                                    1900 9th Ave., Ste. 1100
                                    Seattle, WA 98101
                                    Attention:  CEO
                                    [...***...]

         with a copy to:            Corixa Corporation
                                    1900 9th Ave., Ste. 1100
                                    Seattle, WA 98101
                                    Attention: General Counsel
                                    [...***...]

         If to Gen-Probe:           Henry L. Nordhoff
                                    President and Chief Executive Officer
                                    Gen-Probe Incorporated
                                    10210 Genetic Center Drive
                                    San Diego, CA 92121
                                    Phone: (858) 410-8000

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -17-

<PAGE>

         with a copy to:            General Counsel
                                    [...***...]

     14.2. MODIFICATIONS AND AMENDMENTS. This Agreement shall not be modified or
          otherwise amended except by an instrument in writing executed and
          delivered by each of the parties hereto.

     14.3. INVALIDITY. In the event that any one or more of the provisions (or
          any part thereof) contained in this Agreement or in any other
          instrument referred to herein, shall, for any reason, be held to be
          invalid, illegal or unenforceable in any respect, then to the maximum
          extent permitted by law, such invalidity, illegality or
          unenforceability shall not affect any other provision of this
          Agreement or any other such instrument.

     14.4. ENTIRE AGREEMENT. It is the desire and intent of the parties to
          provide certainty as to their future rights and remedies against each
          other by defining the extent of their undertakings herein. This
          Agreement constitutes and sets forth the entire agreement and
          understanding between the parties with respect to the subject matter
          hereof and is intended to define the full extent of the legally
          enforceable undertakings of the parties hereto, and no promise,
          agreement or representation, written or oral, which is not set forth
          explicitly in this Agreement is intended by either party to be legally
          binding. Each party acknowledges that in deciding to enter into this
          Agreement and to consummate the transactions contemplated hereby it
          has not relied upon any statements, promises or representations,
          written or oral, express or implied, other than those explicitly set
          forth in this Agreement. This Agreement supersedes all previous
          understandings, agreements and representations between the parties,
          written or oral, with respect the subject matter hereof.

     14.5. CONSTRUCTION. The parties have participated jointly in the
          negotiation and drafting of this Agreement. In the even an ambiguity
          or question of intent or interpretation arises, this Agreement shall
          be construed as if drafted jointly by the parties and no presumption
          or burden of proof shall arise favoring or disfavoring any party by
          virtue of the authorship of any of the provisions of this Agreement.
          This Agreement shall be governed by the laws of the State of
          Washington, without giving effect to conflicts of law provisions.

     14.6. ASSIGNMENT. Neither this Agreement nor any of the rights herein
          granted shall be assignable or otherwise transferable by either party
          without the prior written permission of the other party, which shall
          not be unreasonably withheld; provided, however, that each party shall
          have the right to assign, without obtaining the prior written consent
          of the other party, this Agreement or any or all of such rights,
          interests and obligations only to (i) an Affiliate or (ii) a third
          party to whom substantially all of such party's business or assets in
          the subject matter of this Agreement is sold. Additionally, Corixa may
          assign its right to receive payment under this Agreement. All other
          assignments shall be void unless the party seeking assignment has
          first obtained written consent form the other party.

                                             ***CONFIDENTIAL TREATMENT REQUESTED

                                      -18-

<PAGE>

     14.7. RIGHTS UPON INSOLVENCY. All rights and licenses granted to Gen-Probe
          pursuant to this Agreement are, and shall otherwise be deemed to be,
          for purposes of Section 365(n) of Title 11 of the United States Code
          (the "Bankruptcy Code"), licenses to rights of "intellectual property"
          as defined thereunder. Notwithstanding any provision contained herein
          to the contrary, if Corixa is under any proceeding under the
          Bankruptcy Code and the trustee in bankruptcy of Corixa, or Corixa as
          a debtor in possession, rightfully elects to reject this Agreement,
          Gen-Probe may, pursuant to Sections 365(n)(1) and (2) of the
          Bankruptcy Code, retain any and all of Gen-Probe's rights hereunder,
          to the maximum extent permitted by law, subject to Gen-Probe's making
          the payments specified herein.

     14.8. NO IMPLIED LICENSES. No right or license under any know-how, patents
          rights or intellectual property rights of either party is granted or
          shall be granted by implication. All such rights or licenses are or
          shall be granted only as expressly provided in the terms of this
          Agreement.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
day and year first written above.

CORIXA CORPORATION                         GEN-PROBE INCORPORATED
/s/ Steven Gillis, Ph.D.                   /s/ Henry L. Nordhoff
---------------------------                ---------------------------------
Steven Gillis, Ph.D.                       Henry L. Nordhoff
Chairman and CEO                           President and Chief Executive Officer

                                      -19-

<PAGE>

                                    EXHIBIT A

                                LICENSED PATENTS

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                            ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                            ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                            ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                            ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                            ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                                                         APPLICATION
MATTER NO.                        INVENTION TITLE              TISSUE       STATUS           NO.       PATENT NO.
----------                        ---------------            ----------   ----------     -----------   ----------
<S>                               <C>                        <C>          <C>            <C>           <C>
[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]

[...***...]                        [...***...]               [...***...]  [...***...]   [...***...]   [...***...]
</TABLE>

                                            ***CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

<TABLE>
<CAPTION>
                                                        APPLICATION
MATTER NO.   INVENTION TITLE     TISSUE       STATUS    NO.          PATENT NO.
-----------  ---------------  -----------  -----------  -----------  -----------
<S>          <C>              <C>          <C>          <C>          <C>
[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                        APPLICATION
MATTER NO.   INVENTION TITLE     TISSUE       STATUS    NO.          PATENT NO.
-----------  ---------------  -----------  -----------  -----------  -----------
<S>          <C>              <C>          <C>          <C>          <C>
[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
                                                        APPLICATION
MATTER NO.   INVENTION TITLE     TISSUE       STATUS    NO.          PATENT NO.
-----------  ---------------  -----------  -----------  -----------  -----------
<S>          <C>              <C>          <C>          <C>          <C>
[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]

[...***...]    [...***...]    [...***...]  [...***...]  [...***...]  [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

                                    EXHIBIT B

                    MONOCLONAL ANTIBODY PRODUCING CELL LINES

[...***...]
[...***...]
[...***...]
[...***...]

[...***...]
[...***...]

[...***...]
[...***...]
[...***...]

[...***...]
[...***...]

[...***...]
[...***...]
[...***...]
[...***...]
[...***...]

[...***...]
[...***...]
[...***...]

[...***...]
[...***...]
[...***...]

[...***...]
[...***...]
[...***...]
[...***...]
[...***...]

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

                                    Exhibit C

                                   [...***...]

<TABLE>
<CAPTION>
  CASE NO.     COUNTRY    APPN. NO./FILING DATE  PATENT NO./ISSUE DATE    STATUS
-----------  -----------  ---------------------  ---------------------  -----------
<S>          <C>          <C>                    <C>                    <C>
[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
  CASE NO.     COUNTRY    APPN. NO./FILING DATE  PATENT NO./ISSUE DATE    STATUS
-----------  -----------  ---------------------  ---------------------  -----------
<S>          <C>          <C>                    <C>                    <C>
[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
  CASE NO.     COUNTRY    APPN. NO./FILING DATE  PATENT NO./ISSUE DATE    STATUS
-----------  -----------  ---------------------  ---------------------  -----------
<S>          <C>          <C>                    <C>                    <C>
[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
  CASE NO.     COUNTRY    APPN. NO./FILING DATE  PATENT NO./ISSUE DATE    STATUS
-----------  -----------  ---------------------  ---------------------  -----------
<S>          <C>          <C>                    <C>                    <C>
[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]            [...***...]       [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
  CASE NO.     COUNTRY    APPN. NO./FILING DATE  PATENT NO./ISSUE DATE    STATUS
-----------  -----------  ---------------------  ---------------------  -----------
<S>          <C>          <C>                    <C>                    <C>
[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

<TABLE>
<CAPTION>
  CASE NO.     COUNTRY    APPN. NO./FILING DATE  PATENT NO./ISSUE DATE    STATUS
-----------  -----------  ---------------------  ---------------------  -----------
<S>          <C>          <C>                    <C>                    <C>
[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]

[...***...]  [...***...]       [...***...]                              [...***...]
</TABLE>

                                             ***CONFIDENTIAL TREATMENT REQUESTED<PAGE>

                                                                   EXHIBIT 10.76

                              EMPLOYMENT AGREEMENT

      THIS EMPLOYMENT AGREEMENT (the "Agreement") is made as of November 12,
2002 (the "Effective Date") by and between Gen-Probe Incorporated, a Delaware
corporation with offices at 10210 Genetic Center Drive, San Diego, California
92121 ("Gen-Probe"), and [NAME] (the "Executive").

      WHEREAS, the Executive is currently employed as an officer of Gen-Probe;

      WHEREAS, prior to September 15, 2002, Gen-Probe was a wholly-owned
subsidiary of Chugai Pharmaceutical Co., Ltd.;

      WHEREAS, Chugai distributed its Gen-Probe shareholdings to its
shareholders in a "spin off" transaction on September 15, 2002; and

      WHEREAS, the Board of Directors of Gen-Probe (the "Board"), having
considered the proposed spin-off transaction and other circumstances, deems it
in the best interest of Gen-Probe to offer this Agreement to the Executive and
the Executive desires to enter into this Agreement.

      ACCORDINGLY, the parties hereto agree as follows:

1.    TERM OF EMPLOYMENT. This Agreement shall be immediately effective. This
      Agreement, and Executive's employment hereunder, shall be for an
      indefinite term. At any time during the term of this Agreement, either
      party may terminate this Agreement, and Executive's employment, in
      accordance with the provision of Sections 6 and 7 of this Agreement.

2.    POSITION AND DUTIES. The Executive shall serve as [TITLE] of Gen-Probe,
      and shall have commensurate responsibilities and authority. The Board of
      Directors may from time to time particularly specify the Executive's
      duties and authority. The Executive shall not engage in or perform duties
      for any other persons or entities that interfere with the performance of
      his duties hereunder. Any outside board of director positions held by the
      Executive will be subject to approval by the Board of Directors of
      Gen-Probe.

                                       1
<PAGE>

3.    SALARY, BONUS AND BENEFITS,

      (a)   SALARY. During the period of the Executive's employment, Gen-Probe
            shall pay him an annual base salary at the rate the Executive is
            being paid as of the Effective Date. This base salary may be
            adjusted annually by the Board, subject to the terms of this
            Agreement and consistent with the Executive's performance and
            Gen-Probe's policy regarding adjustments in officer compensation
            established from time to time by the Board.

      (b)   BONUS. In addition, at the Board's discretion, the Executive may be
            awarded incentive compensation, in the form of a cash bonus for each
            fiscal year during his employment, based upon performance.

      (c)   BENEFITS. The Executive shall be entitled to participate in the
            employee benefit programs (including but not limited to medical,
            dental, life and disability insurance, 401K retirement plan, and
            vacation program), which may be adopted and maintained by Gen-Probe.
            The Executive may receive such other and additional benefits as the
            Board may determine from time to time in its sole discretion.

4.    EXPENSE REIMBURSEMENT. The Executive shall be entitled to receive prompt
      reimbursement for all reasonable and customary expenses incurred by him in
      performing services hereunder, including all expenses of travel and living
      expenses while away from home on business or at the request of, and in the
      service of Gen-Probe; provided, that such expenses are incurred and
      accounted for in accordance with the policies and procedures established
      by Gen-Probe.

5.    INDEMNIFICATION. Gen-Probe shall indemnify the Executive to the maximum
      extent permitted by law and by the by-laws of Gen-Probe if the Executive
      is made a party, or threatened to be made a party, to any threatened or
      pending legal action, suit or proceeding, whether civil, criminal,
      administrative or investigative, by reason of the fact that the Executive
      is or was an officer, director or employee of Gen-Probe or any subsidiary
      or affiliate thereof, in which capacity the Executive is or was serving at
      Gen-Probe's request, against reasonable expenses (including reasonable
      attorneys' fees), judgments, fines and settlement payments incurred by him
      in connection with such action, suit or proceeding.

6.    TERMINATION. The Executive may terminate his employment hereunder at any
      time, with or without Good Reason (as defined below) upon written notice
      to Gen-Probe. If Executive contends that Good Reason exists for his
      termination, such notice shall specifically and expressly state the
      grounds which he contends constitute Good Reason. Gen-Probe may terminate
      the Executive's employment hereunder at any time, subject to the terms of
      this Agreement, with or without Cause (as defined below) upon written
      notice to the Executive. If this Agreement is terminated, all compensation
      and benefits other than severance benefits

                                       2
<PAGE>

      described in Section 7 below, to the extent applicable, shall immediately
      cease, except that the Executive will be entitled, through the date of
      termination, to payment of his salary and benefits under Gen-Probe benefit
      programs and plans in accordance with their terms.

      As used in this Agreement, "Good Reason" shall mean any of the following
      events that are not consented to by the Executive: (i) a substantial and
      material diminution in the Executive's duties and responsibilities
      hereunder; (ii) the location of the Executive's assignment on behalf of
      Gen-Probe is moved to a location more than 30 miles from its present
      location; (iii) a reduction of more than ten percent (10%) in the
      Executive's base salary or in the Executive's benefits received from
      Gen-Probe; (iv) the failure of Gen-Probe to obtain a satisfactory
      agreement from any other successor to Gen-Probe to assume and agree to
      perform this Agreement; or (iv) a material breach by Gen-Probe of its
      obligations under this Agreement after notice in writing from the
      Executive and a reasonable opportunity for Gen-Probe to cure or
      substantially mitigate any material adverse effect of such breach. The
      Executive's consent to any event which would otherwise constitute Good
      Reason shall be conclusively presumed if the Executive does not exercise
      his rights to terminate this Agreement for Good Reason under this section
      within ninety (90) days of notice of the event.

      As used in this Agreement, "Cause" shall mean any of the following events:
      (i) any act of gross or willful misconduct, fraud, misappropriation,
      dishonesty, embezzlement or similar conduct on the part of Executive; (ii)
      the Executive's conviction of a felony or any crime involving moral
      turpitude (which conviction, due to the passage of time or otherwise, is
      not subject to further appeal); (iii) the Executive's misuse or abuse of
      alcohol, drugs or controlled substances and failure to seek and comply
      with appropriate treatment; (iv) willful and continued failure by the
      Executive to substantially perform his duties under this Agreement (other
      than any failure resulting from disability or from termination by the
      Executive for Good Reason) as determined by a majority of the Board after
      written demand from the Board of Directors for substantial performance is
      delivered to the Executive, and the Executive fails to resume substantial
      performance of his duties on a continuous basis within 30 days of such
      notice; (vi) the death of the Executive; or (vii) the Executive becoming
      disabled such that he is not able to perform his usual duties for
      Gen-Probe for a period in excess of six (6) consecutive calendar months.

                                       3
<PAGE>

7.    SEVERANCE BENEFITS IN CERTAIN EVENTS. If Gen-Probe terminates the
      Executive's employment for reasons other than Cause, or if the Executive
      terminates his employment for Good Reason, the Executive shall be entitled
      to receive as liquidated damages, the following severance benefits:

      (a)   SALARY. The Executive shall continue to receive his base salary, at
            the rate in effect at the time of his termination of employment, in
            monthly installments commencing the first day of the first month
            following termination and continuing for an aggregate period of
            twelve (12) months (the "Salary Continuation Period"); provided,
            however, that if termination under this Section 7 occurs in
            connection with a Change in Control, then the Executive shall
            receive a single lump sum payment, payable within 10 days of
            termination, equal to eighteen (18) months' base salary.

            For purposes of this Agreement, "Change in Control" shall have the
            meaning set forth on Attachment "1" to this Agreement (hereby
            incorporated by reference). For purposes of this Agreement, a
            termination shall be "in connection with" a Change in Control if
            termination occurs within the period six (6) months prior to or
            eighteen (18) months after a Change in Control.

      (a)   (b) BONUS. If termination under this Section 7 occurs in connection
            with a Change in Control then the Executive shall be entitled to
            receive, in lieu of the bonus provided in Section 3(b) and in
            addition to the salary payment described in Section 7(a), above, an
            amount equal to 1.5 times the greater of (i) the Executive's
            targeted level bonus in the year of the termination, or (ii) the
            Executive's highest discretionary bonus in the preceding three
            years. The amount payable shall be paid in the same manner as and on
            the same schedule as the salary compensation paid under subsection
            (a) above. No bonus compensation shall be payable under this section
            7 unless termination occurs in connection with a change in control.

            (c) HEALTH CARE AND LIFE INSURANCE COVERAGE. Continued health care
            coverage under Gen-Probe's medical plan will be provided, without
            charge, to the Executive and his eligible dependents until the
            earlier of (i) one (1) year following the termination date or (ii)
            the first date that the Executive is covered under another
            employer's health benefit program providing substantially the same
            or better benefit options to the Executive without exclusion for any
            pre-existing medical condition. The period of time medical coverage
            continues under this agreement will be counted as coverage time
            under COBRA. Gen-Probe will pay the premium for continued life
            insurance coverage, if any, that the Executive may have elected
            under Gen-Probe's Life Insurance and Supplemental Life Insurance
            plan, subject to payment by the Executive of the portion of such
            premium not contributed by Gen-Probe under such plan, during the
            Salary Continuation Period.

                                       4
<PAGE>

      (d)   401(k) PLAN. The Executive's interest in any unvested contributions
            made by Gen-Probe to the Executive's 401(k) account shall vest as of
            the date of termination.

      (e)   OUTPLACEMENT SERVICES. Gen-Probe agrees to provide Executive with
            outplacement services during the first six months of the Salary
            Continuation Period.

      (f)   TAX MATTERS. All compensation described in this Section 7 will be
            subject to Gen-Probe's collection of all applicable federal, state
            and local income and employment withholding taxes. If any excise tax
            is imposed under Section 4999 in connection with the compensation
            described in this Section 7 and/or in connection with the
            acceleration upon severance of any stock options granted by
            Gen-Probe to the Executive, Executive shall be solely responsible
            for any such excise tax.

      (g)   RELEASE OF CLAIMS. Gen-Probe's obligation to make the payments and
            provide the benefits hereunder shall be conditioned upon Executive's
            execution of a release of all claims, in standard form and content.
            The release shall be mutual and shall also be signed on behalf of
            Gen-Probe.

8.    MISCELLANEOUS.

      (a)   ARBITRATION. Executive and Gen-Probe agree that any and all claims
            or disputes that in any way relate to or arise out of Executive's
            employment with Gen-Probe or the termination of such employment
            (including but not limited to claims under this Agreement or any
            other contract, tort claims, and statutory claims of employment
            discrimination, retaliation or harassment) shall be resolved
            exclusively through final and binding arbitration in San Diego,
            California. Executive and Gen-Probe waive any rights to a jury trial
            in connection with such claims or disputes. The costs of the
            arbitration, including the fees of the arbitrator, shall be borne
            exclusively by Gen-Probe. Any such arbitration shall take place in
            San Diego, California and shall be conducted by a single neutral
            arbitrator who shall be a retired federal or state judge, to be
            appointed by Judicial Arbitration and Mediation Services ("JAMS") in
            accordance with JAMS rules. The applicable procedural rules of JAMS
            shall govern the arbitration. The arbitrator's decision shall be
            delivered in writing and shall disclose the essential findings and
            conclusion on which the arbitrator's decision is based. The parties
            shall be permitted to conduct adequate discovery to allow for a full
            and fair exploration of the issues in dispute in the arbitration
            proceeding. The arbitrator may grant any relief which otherwise
            would have been available to the parties in a court proceeding. The
            decision and award of the arbitrator shall be final and binding, and
            judgment upon the arbitrator's award may be entered by any court of
            competent jurisdiction.

                                       5
<PAGE>

      (b)   GOVERNING LAW. This Agreement shall be construed and enforced in
            accordance with and be governed by the laws of the State of
            California.

      (c)   ENTIRE AGREEMENT. This Agreement sets forth the entire Agreement and
            understanding between the Executive and the Company on the subject
            matter hereof, and supersedes any other negotiations, agreements,
            understandings, oral agreements, representations and past or future
            practices whether written or oral. No provision of this Agreement
            may be amended, supplemented, modified, cancelled, or discharged
            unless such amendment, supplement, modification, cancellation or
            discharge is agreed to, in writing, signed by the Executive and a
            duly authorized officer of the Company (other than the Executive);
            and no provisions hereof may be waived, except in writing, so signed
            by or on behalf of the party granting such waiver.

      (d)   VALIDITY. The invalidity or unenforceability of any provision or
            provisions of this Agreement shall not affect the validity or
            enforceability of any other provision of this Agreement, which shall
            remain in full force and effect.

      (e)   NOTICES. For the purposes of this Agreement, notices, demands and
            all other communications provided for in this Agreement shall be in
            writing and shall be deemed to have duly given when personally
            delivered or mailed by United States certified or registered mail,
            return receipt requested, postage prepaid, addressed as follows:

            If to the Executive:

                                    [ADDRESS]

            If to Gen-Probe:
                                    President and Chief Executive Officer
                                    Gen-Probe Incorporated
                                    10210 Genetic Center Drive
                                    San Diego, California 92121

                       With a copy to:

                                    Vice President, Administration
                                    Gen-Probe Incorporated
                                    10210 Genetic Center Drive
                                    San Diego, California 92121

                                       6
<PAGE>

      (f)   SUCCESSORS. Gen-Probe will require any successor (whether direct or
            indirect, by purchase, merger, consolidation or otherwise) to all or
            substantially all the business and/or assets of Gen-Probe, by
            agreement in form and substance satisfactory to the Executive,
            expressly to assume and agree to perform this Agreement in the same
            manner and to the same extent that Gen-Probe would be required to
            perform it if no such succession had taken place. This Agreement and
            all rights under the Agreement shall be binding upon and shall inure
            to the benefit of and be enforceable by the party's personal or
            legal representatives, executors, administrators, heirs, and
            successors.

      (g)   NO RIGHT TO CONTINUED EMPLOYMENT. Nothing herein shall be construed
            as giving the Executive any rights to continued employment with
            Gen-Probe, and Gen-Probe shall continue to have the right to
            terminate the Executive's employment at any time, with or without
            cause, subject to the provisions of this Agreement.

      In witness whereof, the parties have executed this Agreement.

Executive:                              Gen-Probe Incorporated:

____________________________            By __________________________
[NAME]                                  Henry L. Nordhoff
                                        Chairman, President and Chief Executive
                                        Officer

                                       7
<PAGE>

                                 ATTACHMENT "1"

                        DEFINITION OF "CHANGE IN CONTROL"

            Change in Control. "Change in Control" shall mean a change in
ownership or control of the Company effected through any of the following
transactions:

            (a) any person or related group of persons (other than the Company
or a person that, prior to such transaction, directly or indirectly controls, is
controlled by, or is under common control with, the Company) directly or
indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under
the Exchange Act) of securities possessing more than fifty percent (50%) of the
total combined voting power of the Company's outstanding securities by means of
any transaction or series of transactions; or

            (b) there is a change in the composition of the Board over a period
of thirty-six (36) consecutive months (or less) such that a majority of the
Board members (rounded up to the nearest whole number) ceases, by reason of one
or more proxy contests for the election of Board members, to be comprised of
individuals who either (i) have been Board members continuously since the
beginning of such period or (ii) have been elected or nominated for election as
Board members during such period by at least a majority of the Board members
described in clause (i) who were still in office at the time such election or
nomination was approved by the Board; or

            (c) the stockholders of the Company approve a merger or
consolidation of the Company with any other corporation (or other entity), other
than a merger or consolidation which would result in the voting securities of
the Company outstanding immediately prior thereto continuing to represent
(either by remaining outstanding or by being converted into voting securities of
the surviving entity or another entity) more than 66-2/3% of the combined voting
power of the voting securities of the Company or such surviving entity
outstanding immediately after such merger or consolidation; provided, however,
that a merger or consolidation effected to implement a recapitalization of the
Company (or similar transaction) in which no person acquires more than 25% of
the combined voting power of the Company's then outstanding voting securities
shall not constitute a Change in Control; or

            (d) the stockholders of the Company approve a plan of complete
liquidation of the Company or an agreement for the sale or disposition by the
Company of all or substantially all of the Company's assets.

                                       8
<PAGE>

Schedule to Exhibit 10.64

The preceding form of Employment Agreement was entered into between the Company
and the following individuals:

<TABLE>
<CAPTION>
NAME                  TITLE                                                     EXECUTION DATE
<S>                   <C>                                                       <C>
Niall Conway          Executive Vice President - Sales and Operations           November 12, 2002
James H. Godsey       Executive Vice President - Development                    November 12, 2002
Daniel L. Kacian      Executive Vice President and Chief Scientist              November 12, 2002
R. William Bowen      Vice President and General Counsel                        November 12, 2002
Glen Paul Freiberg    Vice President - Regulatory, Quality &
                              Government Affairs                                November 12, 2002
Lynda A. Merrill      Executive Vice President - Commercialization,
                             Molecular Light Technology Limited                 January 1, 2004
Larry T. Mimms        Vice President - Strategic Planning and Business
                              Development                                       November 12, 2002
Herm Rosenman         Vice President, Finance and Chief Financial Officer       November 12, 2002
Diane De Walt         Vice President - Human Resources                          January 3, 2005
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00080-of-00352.parquet"}]]